Recently, the official website of the State Drug Administration (NMPA) released a new batch of drug approval documents.

(Source: NMPA official website)

The hydrochloride atomization solution is an extension of the bronchial pipe and is used to treat or prevent bronchial spasm caused by adult and adult reversible airway obstructive diseases.

Public information shows that the sandytol is a short -acting β2 receptor agonist and has a rapid effect. It is currently the most widely used drug in clinical treatment of asthma. Savidol is an anti -rotor, consisting of the equivalent L -virus and right rotor, of which only the L -virus produces a diastolic bronchial smoothing muscle; the right rotor has no effect, but it can bind to the beta receptor. Fingers such as shaking. Therefore, left tanoamitol has better safety and has an advantage over the elderly and children's medication. In addition, compared with other a variety of adrenaline β-agonist asthma drugs, the tracheal extension of the left tinttol atomization inhalation solution is strong, the effect is fast, the effect of the effect is long, the selectivity is high, and the side effects are small. Rarely causes heartbeat to accelerate or abnormal arrhythmia.

It is understood that the original research variety of left tinttamol atomization inhalation solution was XOPENEX®, which is the US SEPRACOR Inc. Company (later renamed "Sunovion"). Asthma and COPD. In September 2019, the 3 imitation listing applications of the healthy methalia hydrochloride inhalation solution were approved for approval. The product was named Lishu Tong®, becoming the first ampanitamide inhale in China to be listed in China.

According to Miine.com, the hydrochloride atomization inhalation solution is amazing in the terminal of China's public medical institutions. In 2020, this variety is in Chinese urban public hospitals, county -level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions for short, referred to as Chinese public medical institutions) Terminal sales are only 5 million yuan, and in 2021, it has soared to nearly 200 million yuan. In addition, according to the statistics of Yao Rongyun's data, in 2022, the market sales in my country's hospitals reached 678 million yuan, an increase of 278%year -on -year, a pair of "dark horse".

(Source: Yao Rongyun Database)